Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…
Grupo FarmaBrasil Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different course, towards innovation, manufacturing sovereignty, and strategic influence. Speaking on behalf of Grupo FarmaBrasil, a coalition of the country’s top…
Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…
Brazil Dr. Rodrigues Mota brings two decades of leadership experience within ANVISA, the Brazilian Health Regulatory Authority, where he has held multiple senior positions and now serves as a key architect of the organisation’s strategic transformation. His tenure spans critical periods of regulatory modernisation, digital transformation, and international collaboration, positioning him…
LatAm Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD 560 million; a worrying new report from the Pan-American Health Organisation showing that measles cases are up 29-fold in the…
Brazil After a globe-trotting career that led him to diverse global affiliates, the long-term Takeda executive Rodrigo Rodriguez is going full circle. Returning to where he began his career at the Japanese drugmaker, Rodriguez will be taking on a country full of opportunities and challenges. With more dengue cases than anywhere…
LatAm A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s Laboratorio Vitalis; Pfizer’s joint vaccine effort with PAHO and Argentinian drugmaker Sinergium Biotech, and the epilspsy joint venture between SK Biopharmaceuticals…
Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration. MediPharm Labs Enters Landmark Commercial…
LatAm A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4 million investment in Brazil, and SteinCares’ plasma derivatives deal with Biotest. Record dengue outbreak in Americas kills 7,700 this…
LatAm An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s Celnova Pharma; Grifols’ distribution deal with Gema Biotech; the downturn in Uruguay’s medicinal canibis industry, and Novartis’ increased clinical trial…
Global AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA) bodies and regulatory authorities. The need to optimize drug development and facilitate faster access for patients has focused discussions…
Global DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world at the organization’s Global Annual Meeting 2024. Regulators worldwide recently convened in San Diego for DIA’s Global Annual Meeting 2024 to…
See our Cookie Privacy Policy Here
